Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03AYQ
|
|||
| Former ID |
DNCL003068
|
|||
| Drug Name |
EB-1020
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 2 | [1] | |
| Company |
Euthymics Bioscience
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C15H16ClN
|
|||
| Canonical SMILES |
C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3.Cl
|
|||
| InChI |
1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1
|
|||
| InChIKey |
ACVMJAJGCQUPKX-LIOBNPLQSA-N
|
|||
| CAS Number |
CAS 923981-14-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01939353) An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.